📄 What This Document Is

This is an S-1 registration statement filed with the SEC. It's not for a brand-new IPO. Instead, it's a "resale registration" for an investor, Hexstone Capital LLC, who bought special stock from the company. This filing allows Hexstone to later sell the shares they received to the public market. Think of it as the company helping an investor get permission to sell what they own.

🧬 What The Company Does

👉 In simple terms, Propanc Biopharma is a development-stage biotech company working on new treatments for tough cancers like pancreatic, ovarian, and colorectal cancer.

• Their lead product is called PRP, a combination of "pro-enzymes" (inactive enzyme precursors) designed to stop tumors from growing back and spreading.
• They are based in Australia but incorporated in Delaware. The company is still in the research and development phase and has no approved products or significant revenue from sales.

💰 The Funding Deal & Financial Highlights

The core of this filing is a funding deal that closed on November 4, 2025.

• What Propanc Got: $1,000,000 in gross cash from Hexstone Capital.
• What Hexstone Got:
  • 100 shares of Series C Preferred Stock. These can be converted into common stock, but Hexstone can't own more than 4.99% of the company's total common shares at one time (this can be raised to 9.99% with notice).
  • A Warrant to buy 9,900 more shares of Series C Preferred Stock at $10,000 each. If exercised, that's another potential $99 million for the company.
• Purpose of Funds: The money will be used for general working capital, product development, and corporate purposes.

🧩 Understanding the Capital Structure (The Details)

This deal adds more layers to the company's already complex financial structure.

• Series C Preferred Stock: This is the special class of stock sold to Hexstone. Each share can convert into a variable number of common shares, subject to that ownership cap.
• Common Stock: The basic ownership shares. The company already has many common shares outstanding, plus other classes of preferred stock (Series A & B) and warrants held by other investors.
• Why This Matters: Every time preferred stock is converted or warrants are exercised, it creates new common shares. This "dilutes" the ownership percentage of existing shareholders. This S-1 is necessary because Hexstone's potential future sales would add a large number of shares to the public float.

⚠️ Risk Factors & Big Picture

👍 Potential Strengths:

• Secured $1 million in non-dilutive cash (from the initial sale) to fund operations.
• The warrant provides a potential future funding pipeline worth up to $99 million if the company's prospects improve and Hexstone exercises.

⚠️ Significant Risks:

• Zero Revenue & Operating Losses: As a development-stage company, it burns cash and has no income from products.
• Extreme Dilution Risk: The company's capital structure is a maze of convertible notes, preferred stock, and warrants. Future financing or conversions could massively increase the share count, hurting existing shareholders.
• Dependency on Future Financing: They rely on deals like this one and potential warrant exercises to fund their high-cost biotech research.
• Clinical & Regulatory Risk: Their product candidate, PRP, is still unproven. Most drug candidates fail during clinical trials or never get FDA approval.

🔮 What's Next

• The company will use the $1 million to continue research and development of PRP.
• Hexstone Capital may, over time, convert its preferred stock into common shares and sell them into the public market, as this registration allows.
• Propanc will likely need to pursue additional financing to fund expensive clinical trials and operations, which could lead to more dilutive deals.

🧠 The Analogy

Imagine a startup inventor who needs money to build a prototype. Instead of a traditional loan or selling a piece of the company outright, they give an investor a special "IOU" that can be swapped for pieces of ownership later, plus a coupon to buy more ownership at a set price. This S-1 filing is the inventor helping the investor post a "For Sale" sign on those potential ownership pieces they've earned.

🧩 Final Takeaway

This S-1 reveals a development-stage biotech funding itself through complex, dilutive financial instruments. While the $1 million cash injection is a short-term lifeline, the true story is the highly intricate capital structure that poses major risks for shareholders due to potential massive future dilution. The company's long-term success rests entirely on advancing its cancer drug candidate through costly clinical trials.